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ABSTRACT
Aim of the study. To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple 
sclerosis (MS), to ascertain whether there is a new place for the drug in the treatment regimen of the disease, as well as to de-
termine its safety profile.
Clinical rationale for the study. Due to the increasing availability of new immunomodulatory therapies in multiple sclerosis 
(MS), there is a strong need to re-identify clinical variants and stages of the disease in which mitoxantrone (MTX) can be the 
most effective form of treatment.
Materials and methods. This was a retrospective, non-randomised, observational study evaluating a cohort of 100 MS patients 
(36 relapsing-remitting – RRMS, 36 secondary progressive – SPMS, and 28 primary progressive – PPMS). 59% of the RRMS pa-
tients had discontinued immunomodulatory therapies (IMTs) within the two years preceding MTX infusion. Patients’ disability 
levels, based on the Kurtzke Expanded Disability Status Scale (EDSS) as well as haematological and echocardiographic param-
eters, were assessed at baseline and before every infusion. Magnetic resonance imaging (MRI) were performed at entry and 
after termination of treatment. 
Results. We observed a decrease in the median EDSS score from 4.0 at baseline to 3.5 at the end of MTX infusion in the RRMS 
subgroup, an increase from 4.5 to 5.25 in the PPMS subgroup, and a stable value of 5 points in the SPMS subgroup (p < 0.0001). 
During the treatment period, 97% of patients with initial RRMS were free of exacerbations. The baseline EDSS in the RRMS 
subgroup, as well as the ineffectiveness of previous IMTs, suggested the beginning of conversion to SPMS. We found an 86% 
decrease in the proportion of patients with gadolinium-enhancing lesions on MRI after MTX infusions. There were no life-
threatening adverse events of MTX during the period of evaluation.
Conclusions and clinical implications. Mitoxantrone can be considered as a valuable therapeutic option for patients who are 
on the borderline of RRMS and SPMS. 
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Introduction
Multiple sclerosis (MS) is a chronic, demyelinating dis-
ease of the central nervous system with different patterns of 
evolution and disability accumulation. In the vast majority of 
patients (85-90%), the clinical course starts with a relapsing-
remitting phase (RRMS) that is followed by a secondary pro-
gressive phase (SPMS) in more than half of untreated subjects 
[1–4]. Approximately 10–15% of patients experience gradually 
worsening neurological deficits from the onset without clinical 
relapses: this is known as primary progressive MS (PPMS) [5, 
6]. Mitoxantrone (MTX) is one of the most commonly used 
immunosuppressive drugs in the treatment of MS. MTX is 
a synthetic anthracenedione derivative of doxorubicin, and 
was initially used as an antineoplastic agent. Its mechanism of 
action is through intercalation into DNA strands and inhibi-
tion of topoisomerase II enzyme. In this way, the drug causes 
strand breaks that can delay cell-cycle progression. MTX 
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reduces T lymphocyte proliferation cell numbers, inhibits 
humoral immunity, and decreases cytotoxic T-cell activity 
and the secretion of TH1 cytokines [7–9]. 
In 2000, MTX was approved by the US Food and Drug 
Administration (FDA) for the treatment of aggressive RRMS, 
SPMS and progressive-relapsing MS [10]. Thus, the drug 
can be used both in the induction and escalation treatment 
approaches in patients with MS, and remains one of the few 
agents approved for the treatment of SPMS [11]. However, cur-
rently the European Medicines Agency (EMA) recommends 
the use of MTX in highly active RRMS with rapid disability 
progression in patients for whom alternative treatments are 
not available [12]. Mitoxantrone can also be considered as 
a non-selective form of immune reconstitution therapy for very 
active MS, especially in regions with limited access to newer 
immunotherapies [13, 14]. The MTX cumulative lifetime dose 
has been limited by cardiotoxicity and therapy-related acute 
leukemia (TRAL), initially to 140 mg/m2 and then to 72 mg/
m2 body surface area [12, 15, 16].
Clinical rationale for the study
Due to the increasing availability of new immunomodula-
tory therapies and potentially life-threatening adverse effects 
of MTX, the use of this drug in the treatment of MS has been 
significantly reduced. For this reason, there is a strong need to 
re-identify clinical variants and the stages of multiple sclerosis 
in which MTX can be the most effective form of treatment.
Materials and methods 
This study was approved by the Committee of Bioethics of 
Ludvik Rydygier Collegium Medicum (KB 474/2014).
Patient enrolment and clinical evaluation
We conducted a retrospective, non-randomised, obser-
vational study to assess a cohort of 100 Caucasian patients 
with a diagnosis of MS treated with MTX at the Depart-
ment of Neurology between July 2002 and September 2014. 
Eligible patients were aged 18–70 years, fulfilled the diag-
nostic criteria of multiple sclerosis, had at least one year of 
documented disease duration, and had disability assessed as 
being from 2 to 7 on the Kurtzke Expanded Disability Status 
Scale (EDSS) [17]. Patients with previous immunosuppressive 
therapy, left ventricular ejection fraction (LVEF) measured 
by echocardiography of less than 50%, liver or renal impair-
ment, cancer history, HIV infection, or who were pregnant, as 
well as patients who had undergone intensive steroid therapy 
during the previous month, were excluded from mitoxan-
trone treatment. Disease onset was defined as the year of the 
first symptom. The diagnosis was established according to 
Poser’s criteria [18], McDonald’s criteria [19], and Polman 
et al.’s revisions to McDonald’s criteria [20, 21]. The course 
of the disease was classified as relapsing–remitting (RRMS), 
or secondary progressive (SPMS), or primary progressive 
(PPMS) [1, 2]. 
RRMS was defined as the occurrence of disease relapses 
followed by a complete or partial recovery without progression 
of disability between the bouts. Relapse was defined as the 
occurrence of new, or the worsening of previously described, 
MS-related symptoms lasting more than 24 h in the absence 
of infection or fever. 
The course of multiple sclerosis was classified as second-
ary progressive when an initial relapsing–remitting phase was 
followed by steady worsening of neurological deficits with or 
without superimposed bouts [2, 18].  
PPMS was defined as at least one year of deterioration 
from disease onset with or without superimposed episodes 
of worsening [1, 22]. 
Therefore, the number of relapses in the previous two years 
was determined only for patients with relapsing-remitting and 
secondary-progressive forms of MS. All patients underwent 
a clinical neurological examination during every infusion of 
MTX. Their disability was assessed using Kurtzke’s EDSS scale 
[17]. All patients provided informed consent to having their 
data saved in the database.
Drug administration and safety profile
The routine protocol included seven consecutive cycles of 
MTX - the first five every three months and the last two every 
six months. For each cycle of treatment, the patient was admit-
ted to the Neurology Department for three consecutive days. 
On the first and third days, dexamethasone was administered 
intravenously (iv) at a dose of 8 mg. On the second day, the 
patients received a 30-min infusion of MTX iv at a starting 
dose of 12 mg/m², directly preceded by the administration of 
ondansetron (8 mg iv/dose) [10]. A separate treatment regi-
men was used for an induction therapy in aggressive RRMS: 
this consisted of three cycles of treatment usually at one- or 
three-monthly intervals [10, 23]. Additional courses of steroid 
(methylprednisolone, 1 g iv /day for five days) were allowed 
only for relapses. At the beginning of each treatment cycle, 
blood and urine samples were taken and echocardiography 
was performed. The adverse events were assessed on the 
basis of data obtained from patients either spontaneously 
or on being questioned, as well as monitoring of laboratory 
and echocardiographic parameters. In addition, each patient 
was required to perform a control complete blood count and 
peripheral blood smear after two weeks of MTX infusion. 
MTX adverse reactions were divided according to the time 
from drug administration to their occurrence into either im-
mediate (up to three days after infusion), or early (from day 
4 to one month after infusion), or delayed (more than one 
month after infusion).
MRI assessment 
Magnetic resonance imaging (MRI) exams of brain and 
cervical spinal cord were carried out each time before the 
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first and after the last dose of MTX. All of the studies were 
performed on a 1.5 Tesla MRI scanner using a standardised 
protocol. MRI data was analysed by two neuro-radiologists 
who assessed the number of new gadolinium-enhancing (Gd+) 
lesions on postcontrast T1-weighted scans.
Outcome criteria and statistical analysis
The primary outcome criteria were to compare the efficacy 
of mitoxantrone in various forms of multiple sclerosis, and 
to see if there was a new place for the drug in the treatment 
regimen of this disease. The clinical efficacy of the drug was 
assessed by comparing EDSS score at baseline to that after the 
last MTX infusion, as well as the proportion of exacerbation-
free patients. The term ‘improvement’ was used when the 
median EDSS score was lower at the end of the treatment 
than at baseline; the term ‘stabilisation’ was used when the 
median EDSS score did not change after MTX therapy; and 
the term ‘deterioration’ was used when the median EDSS 
score after treatment was higher than at the beginning.  The 
secondary outcome criteria were decreases in the number of 
Gd+ lesions on MRI scans after the last MTX infusion com-
pared to the baseline study, and in the frequency and profile 
of treatment-adverse reactions. The treatment side effects 
were then correlated with the clinical course of the disease 
and with gender. An assessment of the above-mentioned 
outcomes was also performed in patients who prematurely 
ended MTX therapy.
The differences between the investigated groups were 
calculated by Student’s t-test for parametric data and U Mann-
Whitney test for nonparametric data. Chi-squared test was 
used to compare proportions in groups.  Statistical significance 
was considered for a p-value ≤ 0.05. All calculations were 
performed with a Statistica 12.1 application.
Results 
Clinical characteristics 
The investigated group consisted of 64 women (64%) and 
36 men (36%) with a mean age of 44.3 ± 10.8 years. The mean 
age at disease onset was 34.9 ± 11.2 years. The mean disease 
duration was 9.5 ± 7.1 years. The median EDSS score at base-
line was 4.5, range 2-7. 36 of the patients (36%) were assigned 
to the RRMS subgroup, 36 to the SPMS subgroup (36%), 
and 28 (28%) to the PPMS subgroup with respect to disease 
course. The mean time to transition to a secondary progressive 
course of MS was 12.1 ± 6.4 years. We did not find significant 
clinical differences between women and men. The clinical and 
demographic characteristics of the investigated groups are set 
out in Table 1. 19 of the patients had used immunomodula-
tory therapies (IMTs) within the two years preceding MTX 
infusion: glatiramer acetate — three, natalizumab — one, 
interferon beta — 13, glatiramer acetate and interferon beta 
at intervals — two. The median time of immunomodulatory 
therapy among these patients was two years. Among patients 
with relapsing–remitting onset of MS, 54 had experienced one 
or more bouts within the two years preceding mitoxantrone 
therapy (Tab. 1). We assessed the primary and secondary 
outcome criteria, as well as the treatment of adverse events in 
all investigated patients.
Clinical outcomes 
The mean time of treatment was 1.9 ± 0.6 years. The mean 
number of cycles of MTX infusion was 6.8 ± 1.97, and the 
median total dose was 140 mg (range 30–140). 36 patients 
did not complete the full course of MTX therapy for the 
following reasons: 16 patients with RRMS were switched to 
immunomodulatory treatment; 14 patients felt the drug was 
ineffective; and six patients withdrew due to adverse events. 
In the investigated group, the median EDSS score at baseline 
was 4.5 (range 2–7) and remained stable during the treatment 
period. Comparing the EDSS score at baseline and after the 
last MTX infusion, we found that disability was worse by at 
least 0.5 EDSS point in 27 patients, by at least one point in 
10 patients, and improved in 31 patients (≥ 0.5 point). The 
remaining 47 patients had no change in EDSS score during the 
treatment period. The median time to identify an improvement 
on the EDSS scale was three months (range 3–18). The mean 
time to disability progression was 10.5 ± 3.7 months. We found 
statistically significant differences in disability progression 
with regard to the variant of multiple sclerosis, with the dura-
tion of relapsing-onset MS (RRMS/SPMS), and with gender 
(Tab. 1, 2). Among the patients with confirmed disability 
progression ≥ 1.0 EDSS point, there were no RRMS patients; 
eight patients had PPMS, and the remaining two had SPMS 
(p = 0.0004). We observed a decrease in the median EDSS 
score from 4.0 at baseline to 3.5 at the end of MTX infusion 
in the RRMS subgroup and an increase from 4.5 to 5.25 in the 
PPMS subgroup. In the subgroup of patients with SPMS, the 
median EDSS score at baseline was 5.0 and remained stable 
during the treatment period. We found statistically significant 
differences in EDSS score between the baseline and the end of 
MTX infusion in patients who had had at least one exacerba-
tion within the 12 months preceding mitoxantrone therapy 
(Tab. 2). During the treatment period, one person experienced 
one relapse, and another two relapses, of multiple sclerosis. 
Thus, 70 patients with an initial relapsing–remitting course of 
MS were free of exacerbations. 
Assessment of brain MRI activity
43 patients had at least one gadolinium-enhancing lesion 
at baseline MRI. Of these, in 30 subjects they were located only 
in the brain, in eight patients only in the spinal cord, and in 
the remaining five patients in both locations simultaneously. 
The median number of  baseline Gd+ lesions was 2 (range 
1–4). At the beginning of the treatment, T1-Gd+ lesions 
were found in 24 patients with RRMS, 12 with SPMS, and 
seven with PPMS (p = 0.00129). At the end of mitoxantrone 
therapy, gadolinium-enhancing MRI lesions were noted in 
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Table 1. Demographic and clinical characteristics of patients 
General Women Men p-value
No. of patients 100 64 36
Age (years)
Mean (SD)
Median (range)
44.3 (10.8)
45 (20-68)
44.0 (11.6)
45 (20–68)
44.7 (9.5)
43 (30–63)
0.7507
Age at disease onset (years)
Mean (SD)
Median (range)
34.9 (11.2)
34 (13–61)
34.5 (11.4)
32.5 (13–58)
35.8 11.0)
35 (17–61)
0.5738
Disease course (at the beginning of treatment)
Relapsing–remitting, n (%) 
Secondary progressive, n (%) 
Primary progressive, n (%) 
36 (36) 
36 (36)
28 (28)
26 (40.6)
24 (37.5)
14 (21.9)
10 (27.8)
12 (33.3)
14 (38.9)
0.1695
Disease duration (years)
Mean (SD)
Median (range)
9.5 (7.1) 
7 (1–32)
9.8 (7.2)
6.5 (1–32)
8.9 (6.8)
8 (1–24)
0.6614
Systems involved at onset; n of patients
Sensory
Motor
Sensory and motor
Optic neuritis 
Brainstem
Cerebellar
Spinal
Polysymptomatic
13
12
2
19
6
17
21
10
11
9
2
10
4
11
10
7
2
3
0
9
2
6
11
3
0.3466
EDSS score at baseline
Mean (SD)
Median (range)
4.6 (1.1) 
4.5 (2–7)
4.7 (1.1) 
4.5 (2–6.5)
4.6 (1.1) 
4.5 (2.5–7)
0.9748
Relapses before MTX infusion
12 months
24 months
44
54
32
38
12
16
0.7972
Change in EDSS score after MTX infusions
Improvement
Stabilisation
Deterioration
31
42
27
25
22
17
6
20
10
0.0450
MTX adverse reactions
a) immediate 
Nausea
Vomiting
b) early 
Leucopenia (< 3,000/mmᶟ)
Urinary and upper respiratory tract infection
Alopecia
c) delayed
Decreased LVEF
29
13
21
14
12
7
21
12
17 
9 
12
3
8 
1
4 
5 
0
4
0.2626
0.0226
0.0686
0.9808
0.0056
0.2269
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Table 2. Change in EDSS score after MTX infusions
Type of parameter Change in EDSS score
Improvement Stabilisation Deterioration p-value
Clinical course of MS
RRMS 
SPMS 
PPMS 
22
9
0
11
21
10
3
6
18
  < 0.0001
Disease duration
Relapsing-remitting onset MS 
< 5 years
5–10 years
> 10 years
PPMS
< 5 years
5–10 years
> 10 years
12
7
12
0
0
0
2
9
21
7
3
0
2
6
1
15
2
1
 
 0.0017
 
 
 
 0.3705
Relapses in the 12 months prior to MTX
No
≥ 1
6
25
19
13
3
6
 0.0046
Relapses in the 24 months prior to MTX
No
≥ 1
6
25
10
22
2
7
  0.5405
T1-Gd+ lesions at baseline MRI 
No
≥ 1
9
22
28
14
20
7
  0.0006
six patients. In four of them, these lesions were located in the 
brain, and in two in the spinal cord. We found a statistically 
significant improvement in EDSS score between the beginning 
and the end of MTX infusion in patients who had at least one 
gadolinium-enhancing lesion at baseline MRI (p = 0.00046) 
(Tab. 2). The median number of baseline Gd+ lesions was 1 in 
the subgroup of patients who experienced disability reduction 
after MTX therapy, and 0 in the subgroup of patients with 
stabilisation or progression of disability at the end of this 
treatment (p = 0.0038).
Adverse events
No patient developed acute myeloid leukemia. There was 
no congestive heart failure. Seven patients developed asymp-
tomatic left ventricular ejection fraction decreased to less than 
50%. Nine women experienced dysmenorrhea. There were no 
serious infections, 10 patients experienced mild urinary tract 
infections, and four patients experienced upper respiratory 
tract infections that resolved with antibiotic therapy. Alopecia 
was transient and minor for 12 women, and no patient de-
veloped moderate or severe alopecia. We found a statistically 
significant difference in the development of vomiting and 
alopecia between men and women (Tab. 1). There were no 
statistically significant correlations between the clinical MS 
variant and the incidence of MTX adverse events. 
Discussion 
The efficacy and safety profile of mitoxantrone have been 
evaluated in many previous studies, and these became the 
basis for the approval of this treatment by the FDA. However, 
most of these trials did not assess a comparative analysis of 
the differences in response to treatment between patients with 
RRMS and SPMS, and none of them focused on patients on 
the borderline of RRMS and SPMS [10, 24–26]. 
In the presented study, we performed a post hoc analysis 
of the influence of MTX on the clinical and neuroradiologi-
cal activity of different MS variants. Regarding the primary 
outcomes, we demonstrated the efficacy of mitoxantrone in 
the reduction of disability progression depending on the 
variant and stage of the disease. We found an improvement in 
the EDSS score in 61% of patients with RRMS and in 25% of 
patients with SPMS at the end of MTX therapy. The propor-
tion of disability progression-free patients during the period 
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of evaluation was 92% in the RRMS subgroup and 83% in the 
SPMS subgroup. It is noteworthy that the mean time to achieve 
an improvement in EDSS score was three months. Taking into 
account all patients with relapsing-onset MS, MTX prevented 
disability progression in 87.5% of them, and the efficacy of 
the drug was significantly higher in subjects with a shorter 
disease duration. In this subgroup, 97% of patients were free of 
relapses during the treatment period. Esposito et al. compared 
the efficacy of MTX in 79 patients with RRMS and 210 patients 
with SPMS [27]. The authors found 94.9% of RRMS patients 
free from disability progression during the treatment period. 
The mean EDSS score improved in the RRMS subgroup from 
3.0 to 2.6 after treatment with MTX. The improvement was 
usually observed during the first trimester of treatment, which 
makes the results of this Italian study consistent with our 
data. Compared to our study, Esposito et al. obtained a lower 
proportion of patients with SPMS (71%) free from disability 
accumulation, and a lower proportion of relapsing-onset MS 
patients (50%) free of bouts during the treatment period. This 
discrepancy might be explained by the lower MTX cumulative 
dose (61 mg/m²) used by the authors. 
Many studies have confirmed the efficacy of mitoxantrone 
in the treatment of RRMS patients with high disease activity. 
In these cases, mitoxantrone reduced the annualised relapse 
rate, the disability progression, and the number of demyelin-
ation lesions with contrast enhancement [13, 28–30]. These 
figures are comparable to our findings in the subgroup of 
patients with RRMS. In our study, among all relapsing-onset 
MS patients 26% were exposed to immunomodulatory drugs 
during the two years preceding MTX infusions. Termination 
of IMTs was due to its lack of efficacy in the course of high 
disease activity or the initial phase of conversion from RRMS 
to SPMS. For this reason, MTX remained the most beneficial 
therapeutic option for most of these patients. The identifica-
tion and treatment planning for patients with RRMS who 
started conversion to SPMS was a particular challenge. In the 
natural course of MS, the conversion from RRMS to SPMS is 
observed between 5.8 and 19.1 years from disease onset. This 
timespan may be a consequence of the fear of recognising 
the next stage of the disease and, at the same time, the lack 
of efficacy of the IMTs used. Furthermore, it may result from 
the application of differing diagnostic criteria. Difficulties in 
identifying the early stages of SPMS can lead to diagnostic 
uncertainty and inadequate treatment. Sand et al. determined 
the average delay in diagnosis of SPMS to be 2.9 ± 0.8 years 
[31]. In our study, the patients were distributed into SPMS 
according to the Lublin and Reingold criteria [2] in which 
a steady worsening of neurological symptoms for at least six 
months, independent of bouts, was a cardinal condition for 
diagnosis. However, in some of the studies conducted so far, 
the observation period of the neurological deficit deterioration 
needed to establish the diagnosis of SPMS was 12 months, and 
the other proposed criteria included only a 3-month observa-
tion assuming a minimum disability greater than or equal to 
4 EDSS points [32]. For this reason, the baseline EDSS score of 
4 in the RRMS subgroup of our patients could be an additional 
argument supporting the beginning of the transition to SPMS. 
Thus, our results may indicate that there is a new place 
for mitoxantrone in the treatment of MS for patients on the 
borderline of RRMS and SPMS. The multicentre, randomised, 
double-blind, placebo-controlled study published by Hartung 
et al. revealed the efficacy of 12 mg/m² of mitoxantrone in the 
treatment of worsening RRMS and SPMS patients compared to 
placebo [10]. The authors obtained a reduction in the progress 
of disability and the annualised relapse rate by 64% and 60% 
respectively in the mitoxantrone group. However, this study 
did not assess the efficacy of MTX in patients who are on the 
borderline of RRMS and SPMS. 
Our study found an 86% decrease in the proportion of 
patients with gadolinium-enhancing lesions after MTX infu-
sions, which was in line with the results presented by Edan 
et al. and Le Page et al. [24, 28]. Additionally, we showed that 
both the presence of at least one Gd+ lesion at baseline MRI, 
and at least one relapse within the 12 months preceding MTX 
therapy, significantly improved EDSS score after treatment. 
In our group, no PPMS patient was free of disability progres-
sion after MTX therapy, which confirms previous findings of 
ineffectiveness of the drug in this MS variant [33]. However, 
it should be noted that in 35.7% of patients in this subgroup, 
EDSS score remained stable during the treatment. In our study, 
the highest percentage of men was in the PPMS subgroup, and 
the highest percentage of women was in the RRMS subgroup, 
which could explain the worse clinical response of men than 
women to mitoxantrone. 
In the investigated group, mitoxantrone was generally 
well tolerated. There were no life-threatening adverse events 
of MTX during the treatment period. Nausea was the most 
frequently reported side effect. An asymptomatic decreased 
left ventricular ejection fraction to less than 50% was found in 
7% of patients, which was comparable to the results obtained 
in the study by Esposito et al. [27]. Leukopenia was reported 
in 21% of patients and was transient in each case. 
A valuable finding of our study is the occurrence of some 
adverse effects (vomiting and alopecia) found significantly 
more often in women than in men. Due to the lack of data on 
this issue in the literature, it was impossible to compare these 
results with those of other studies. In our study, all reported 
short-term adverse events of MTX were less frequent than in 
previous reports [10, 24, 34–36]. Unfortunately, we have not 
conducted a long-term assessment of the MTX safety profile 
in our group, which is one of the limitations of the study. For 
this reason, we were unable to monitor the left-ventricular 
ejection fraction up to five years after MTX therapy cessation, 
as recommended by EMA. So, the percentage of patients who 
have experienced cardiotoxic effects of the drug may be under-
estimated. Furthermore, the number of subjects using IMTs 
prior to MTX therapy was small, mainly due to administrative 
reasons and the time restrictions regarding this treatment in 
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Poland until 2014 [37]. Therefore, mitoxantrone became the 
first line treatment in 74% of subjects with relapsing-onset 
MS. Another limitation was the lack of MRI assessment for 
new or enlarging T2 lesions. However, the main limitation of 
our study remains its retrospective nature.
Clinical implications/future directions
The results of our study suggest that mitoxantrone is a valu-
able therapeutic option for patients with highly active MS in 
whom other treatments are ineffective or unavailable. The use 
of MTX can be justified in patients with SPMS, especially in 
the context of the unmet therapeutic need for this MS variant. 
The drug is useless in patients with PPMS. 
Finally, our findings indicate that mitoxantrone may be 
considered in patients at the initial stages of conversion from 
RRMS to SPMS in the case of ineffectiveness of the available 
IMTs or contraindications for their use. To the best of our 
knowledge, this is the first study to have indicated a place 
for mitoxantrone in the treatment of patients who are on the 
borderline of RRMS and SPMS. 
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